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Protein expression has been compared in human substantia nigra specimens from Parkin-
son’s disease (PD) patients and from controls, and 44 proteins expressed in this midbrain
region were identified by peptide mass fingerprinting. Among them, nine showed changes in
their abundance. L and M neurofilament chains are less abundant in PD specimens, whereas
peroxiredoxin II, mitochondrial complex III, ATP synthase D chain, complexin I, profilin, L-type
calcium channel d-subunit, and fatty-acid binding protein are significantly more present in PD
samples than in controls. Besides the consolidated view of oxidative stress involvement in PD
pathogenesis, suggested by overexpression of mitochondrial and reactive oxygen species
(ROS)-scavenging proteins, these results indicate a possible potentiation mechanism of
afferent signals to substantia nigra following degeneration of dopaminergic neurons.
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1 Introduction
Parkinson’s disease (PD) is the second most common
neurodegenerative disorder after Alzheimer’s disease
(AD), with a prevalence of about 2% among people over
the age of 65 years [1, 2]. The characteristic motor
symptoms are associated with the depletion of dopami-
nergic melanin-containing neurons in the substantia nigra
pars compacta (SNpc) and a consequent loss of dopa-
mine in the striatum [1]. Another important pathological
feature is the presence, especially in SNpc neurons, of
eosinophilic cytoplasmic inclusion bodies (Lewy bodies,
LB) [1, 3, 4]. LB show a strong staining with anti-a-synu-
clein antibodies [5], a presynaptic protein involved in a
familial form of the disease [6, 7], present as the main
filamentous component [8–10]. In vitro studies showed
that both mutated and wild-type a-synucleins do form
fibrils similar to those of LB; moreover, a-synuclein mole-
cules carrying either one of the two point mutations
observed in the familial PD will aggregate faster than the
wild-type protein [11–13]. Recently, the effects of chan-
ges in the a-synuclein sequence on the enhanced sus-
ceptibility of cells to reactive oxygen species (ROS) have
been reported [14–17], providing a pathogenic link be-
tween a-synuclein anomalies and a putative role of ROS
in the cell death mechanisms in PD [18–21].
Substantia nigra (SN) is a preferential candidate to oxida-
tive damage, since it contains oxidizable dopamine, neu-
romelanin, polyunsaturated fatty acids, iron, and relatively
low antioxidant complement [21]. In this context, mito-
chondria are involved in a number of cellular reactions
that potentially lead to the formation of ROS, like super-
oxide anions, hydroxyl radicals, and hydrogen peroxide.
Complexes I and III in particular are associated with
superoxide production, and the inhibition of these com-
plexes results in increased free radical production. Mito-
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chondria contain antioxidant defence systems, such as
glutathione, catalase, and superoxide dismutase, to
carefully balance free radical production and detoxifica-
tion. Oxidative stress is believed to be important in the
ageing process and details of how ROS are produced
from various intra- and extracellular sources as well as the
cellular defence mechanisms and responses to oxidative
stress have recently been extensively reviewed [22, 23].
Nowadays, the occurrenceof a tight associationof proteins
to form insoluble supramolecular aggregates is considered
to be the basis of a number of neurological diseases, both
familial and sporadic. Self-aggregation of a-synuclein,
wrong folding of the prion protein, defective cleavage of the
amyloid b-peptide and hyperphosphorylation of the tau
protein all lead to changes in the dynamics of cytosolic
proteins and eventually the formation of macroscopic
aggregates in PD, spongiform encephalopathy, and AD,
respectively [8, 24]. An analysis of the water dynamics in ex
vivo specimens ofSNpchas showna differential deposition
of cytosolic proteins with respect to age-matched controls
[25]. It has recently been proposed that misfolded a-synu-
clein could form channels in dopamine storage vesicles,
thus contributing to the formation of cytoplasmic ROS due
to dopamine oxidative catabolism [26].
In the present work, we describe a proteomic analysis of
SN tissue in order to evaluate changes in the expression
level of proteins that could provide information on the
pathogenetic mechanism and on the pathways herein
involved. To this purpose, we performed a two-dimen-
sional electrophoretic (2-DE) separation of proteins
extracted from ex vivo specimens from controls and PD
patients. Forty-four proteins have been identified by pep-
tide mass fingerprinting and their expression levels have
been compared and statistically evaluated. Among them,
nine proteins showed differential expression in PD
patients respect to age-matched controls.
2 Materials and methods
2.1 Chemicals
Immobilized pH gradient (IPG) strips, IPG buffer, acryl-
amide, and Coomassie Brilliant Blue R-250 were pur-
chased from Amersham Biosciences (Uppsala, Sweden).
Modified trypsin was from Promega (Madison, WI, USA).
ZipTipC18 were from Millipore (Bedford, MA, USA). The
protease inhibitor mix (from Sigma Chemical, St. Louis,
MO, USA) contained 4-(2-aminoethyl)benzenesulfonyl
fluoride (AEBSF), pepstatin A, trans-epoxysuccinyl-L-leu-
cylamido(4-guanidino)butane (E-64), bestatin, leupeptin,
and aprotinin, and was used according to manufacturer’s
instructions. All other chemicals were obtained from
Sigma Chemical and used without further purification.
2.2 Tissues
Specimens of human SN from four patients having known
PD history (sex 3 M, 1 F, aged 756 3 years; deceased 13
6 2 years after diagnosis; postmortem delay 4 h 38 min6
26 min; brain weight 1156 6 94 g) were provided by the
Nederlandse Hersenbank (the Netherland’s Brain Bank),
Amsterdam. Each specimen was accompanied by histo-
pathological report, showing depletion of pigmented
dopaminergic neurons and the occurrence of extracellular
neuromelanin granules as well as LB in surviving neurons.
Four control specimens (sex 3 M, 1 F, aged 70 6 8 years;
postmortem delay 6 h 19 min 6 1 h 11 min; brain weight
1441 6 127 g), not affected by neurodegenerative dis-
orders, have been obtained from the same brain bank,
also with histopathological report. SN have been excised
from thawed autoptic specimens in order to refine the
region of interest by cutting the surrounding unpigmented
area using ceramic tools to avoid metal contamination of
the samples. For less-pigmented PD tissues, a corre-
sponding area has been removed. When present, blood
clots have been removed before sample processing.
2.3 Protein extraction
Specimens (0.5–0.7 g) were homogenized (20 up-and-
down strokes with a Teflon homogenizer followed by five
passages through a 22-gauge needle) in 3 mL lysis solu-
tion (7 M urea, 2 M thiourea, 4% v/v CHAPS, 0.05 mL pro-
tease inhibitor mix) per mg tissue. After centrifugation at
21 0006g for 30 min at 207C supernatants were recov-
ered; protein content was estimated with the 2D-Quant kit
(Amersham Biosciences).
2.4 2-DE and data analysis
2-DE was performed according to Jacobs [27], with some
modifications. Samples (, 1 mg for Coomassie staining,
, 100 mg for silver staining) were diluted to 250 mL with a
buffer containing 7 M urea, 2 M thiourea, 4% CHAPS, 0.5%
IPG buffer 3–10, 2 mM tributylphosphine, and traces of
bromophenol blue and loaded onto 13 cm IPG DryStrips
with a nonlinear pH3–10gradient by in-gel rehydration (1 h
at 0 V, 10 h at 30 V). IEF was performed at 167C on an IPG-
phor (Amersham Biosciences) according to the following
schedule: 1 h at 200V, 30min of a lineargradient to 3500V,
3 h at 3500 V, 2.5 h of a linear gradient to 8000 V, 6 h at
8000 V. Prior to SDS-PAGE, the IPG strips were equili-
brated for 2630 min in 50 mM Tris-HCl, pH 8.8, 6 M urea,
30% glycerol, 2% SDS, and traces of bromophenol blue
containing1%DTT for the first equilibration step and2.5%
iodoacetamide for the second one. SDS-PAGE was per-
formed using 12.5% T, 2.6% C 1.5 mm thick separating
polyacrylamide gels without stacking gel, using a Hoefer
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SE 600 system (Amersham Biosciences). The second di-
mension was carried out at 45 mA/gel at 167C and was
terminated when the bromophenol dye front had migrated
to the lower end of the gels. Carbamylated pI calibration
markers (Amersham Biosciences) and molecular mass
marker proteins (14–66 kDa from Sigma Chemical) were
used for calibration of the molecular mass. The gels were
stained either with Coomassie Brilliant Blue R-250 or
according to Sinha’s silver staining method [28]. After
staining, gels were scanned with the ImageMaster Labs-
can V3.0 (Amersham Biosciences) and images were ana-
lyzed with ImageMaster 2D Elite V4.01 software package
(Amersham Biosciences). Coomassie-stained spots were
quantified on the basis of their relative volume (the spot
volume divided by the total volume over the whole set of
gel spots) and statistically analyzed according to the non-
parametric Wilcoxon test. Relationships were considered
statistically significant when p, 0.05.
2.5 Tryptic digestion of 2-DE gel spots
Coomassie-stained spots were manually excised and
destained overnight with 40% ethanol in 25 mM ammo-
nium bicarbonate. Gel pieces were washed twice with
25 mM ammonium bicarbonate and desiccated three
times with acetonitrile. Each piece was then reswollen in
25 mM ammonium bicarbonate containing 1.2 mg of
modified porcine trypsin and digestion proceeded over-
night at 377C. Peptides were extracted by sonication in
25 mM ammonium bicarbonate and loaded on ZipTipC18.
2.6 MALDI-TOF-MS
Each peptide sample was eluted from ZipTipC18 with a satu-
rated solution of a-cyano-4-hydroxycinnamic acid in 70%
acetonitrile and0.2%TFAand0.5mLwasspotteddirectlyon
aMALDI target plate.MALDImass spectra were acquired in
the positive reflectron ionmodewithdelayedextractionona
Reflex III timeof flight instrument (BrukerDaltonics, Bremen,
Germany) equipped with a 337 nm nitrogen laser. Ion accel-
eration voltagewas set to 20.00 kV, the reflector voltagewas
set to 23.00 kV and the first extraction plate was set to
17.05 kV. Mass spectra were obtained by averaging 600
laser shots. Calibration of the spectra was performed
internally by a two-points linear fit, using the autolysis prod-
ucts of trypsin atm/z 842.50 and 2211.10.
2.7 Database search
Database search with the peptide masses was performed
against the Swiss-Prot database using the PeptIdent
search algorithm (http://www.expasy.ch/tools/pepti-
dent.html). Mass tolerance for the monoisotopic peptide
masses was set to 50 ppm.
3 Results
Proteins were extracted from four control specimens and
four PD specimens, and analyzed in parallel by 2-DE,
using both Coomassie Brilliant Blue and silver staining.
With silver staining 50–100% more spots could be visu-
alized (Fig. 1). By considering all the data sets, no signifi-
cant differences were found between controls and PD
patients in terms of appearance, disappearance or shift of
any spot, with both staining methods.
In order to investigate how the overall expression of pro-
teins is potentially affected in PD with respect to controls,
142 spots were selected for further analysis from the
Coomassie-stained gels. Only spots that were mostly
expressed or better focalized were chosen. In both spe-
cimens, the amount of protein present in each spot was
densitometrically measured and statistically evaluated.
Table 1 (see Addendum) reports isoelectric points and
molecular weights, as deduced from the gel, and statis-
tical analysis of spot volumes, according to Wilcoxon test,
for each protein. Figure 2 shows the position of the 142
spots in a Coomassie-stained gel from a control speci-
men.
To build a map of the proteins extracted from human SN
specimens, we tried to identify by peptide mass finger-
printing the spots that had been selected for statistical
analysis. Spots were excised, both from control and PD
gels, and digested with trypsin. Peptide masses were
Figure 1. Silver-stained 2-DE gel of proteins extracted
from an autoptic SN specimen of a control patient.
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Figure 2. Coomassie-stained 2-DE gel of proteins extracted from an autoptic SN specimen of a
control patient. Spots are labeled according to Table 1.
used to query the database. In order to evaluate protein
identifications, we considered not only the percentage of
sequence coverage (at least 20%), as indicated in Table 1,
but also thenumberofmatchingpeptides (at least five) and
the gap between the accepted protein and the first ex-
cluded one in the list of candidates provided by the data-
base search (at least a difference of three peptides). The
procedurewas successful, and44proteinswere identified.
As it can be noticed from Table 1 (Addendum), nine of the
44 proteins are differentially expressed in PD tissues with
respect to controls (p , 0.05). L and M neurofilament
chains (spots 4 and 1, respectively) are less abundant in
PD specimens, which is in keeping with degeneration of
SNpc neurons. The other seven proteins, namely peroxi-
redoxin II (spot 89), mitochondrial complex III (spots 91
and 93), ATP synthase D chain (spot 87), complexin I
(spot 127), profilin (spot 129), L-type calcium channel d-
subunit (spot 123), and fatty-acid binding protein
(spot 130), are significantly more expressed in PD sam-
ples than in controls.
4 Discussion
Proteomics is a powerful methodology to investigate
how protein expression is affected in the pathogenesis of
a disease process. Nevertheless, there are to date a
limited number of reports in the field of neurodegenera-
tive disorders compared to other classes of diseases
[29]. One of the limits of the technique is the limited
number of protein spots that can be visualized on a sin-
gle gel. Only the most expressed proteins are recog-
nized, and very large or very small proteins cannot be
adequately resolved. Also the range of pI values is a
matter of concern; although nonlinear pH gradients are
 2004 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.proteomics-journal.de
Proteomics 2004, 4, 3943–3952 Proteome analysis of human substantia nigra in Parkinson’s disease 3947
commonly used, proteins having extreme pI values can-
not focalize properly. Moreover, hydrophobic membrane
proteins are difficult to resolve. Nonetheless, information
on major proteins may also be of use, mainly for those
proteins involved in the energetic metabolism of the cell.
In a preliminary report, we observed that (mitochondrial)
Mn-SOD and dihydropteridine reductase were increased
twofold in PD with respect to controls, although speci-
men variability did not allow to have statistically signifi-
cant figures [30].
Among the 44 proteins identified in this work, nine show
significant changes in their level of expression. In partic-
ular, higher expression of peroxiredoxin II is in agreement
with the oxidative stress hypothesis in PD [18, 23]. Per-
oxiredoxin II has been recently reported to be more
expressed in the frontal cortex of PD, AD, and Down
syndrome patients [31]. Peroxiredoxins are sacrificial
antioxidants, i.e., instead of catalyzing ROS oxidation/
reduction they react themselves with ROS. In this pro-
cess, available protein thiols (Cys-SH) are oxidized to
sulfinyl residues (Cys-SO2
2) with a consequent reduction
of the pI. To the peroxiredoxin family belongs the DJ-1
protein as well; recently, a large deletion in the DJ-1 gene
was reported to cosegregate with early-onset PD in a
consanguineous Dutch family; moreover, a L166P muta-
tion was found in an Italian family [32]. DJ-1 is known to
interact with c-myc and to increase cell transformation,
and to inhibit the RNA-binding ability of a cAMP-respon-
sive multiprotein complex that includes glyceraldehyde-
3-phosphate dehydrogenase [19]. It has also been sup-
posed that DJ-1 acts as a ROS scavenger, thus modulat-
ing oxidant stress conditions. DJ-1 behaves as a hydro-
peroxide-responsive protein, that is converted into a var-
iant with a more acidic pI in response to oxidative stress,
suggesting a function as an antioxidant protein [33, 34].
These authors also described a similar behavior for per-
oxiredoxins in the case of human umbilical vein endothe-
lial cells in response to oxidative stress [35].
Actually, there are suggestions that ROS, by-products of
the oxidative metabolic pathway, may damage cell mem-
branes through addition to unsaturated bonds in the lipid
bilayer [18]. Oxidant stress conditions may, in turn, be
strictly connected to excitotoxicity or to mitochondrial
dysfunction [23, 36].
A reduced complex I activity was first identified in the SN
of post mortem PD brain [23, 37]. Other brain areas
showed normal oxidative phosphorylation activity [23, 37,
38]. Complex I defect is specific to PD and selective for
the SN, but not related to the formation of LB [23]. Addi-
tional defects in complexes II and III were reported as well
[39, 40]. Mitochondrial changes in PD could either be the
result from inherited mutations in the mitochondrial
respiration proteins or a consequence of environmental
factors and/or sporadic somatic mutations that compro-
mise normal mitochondrial activity [23]. We report that
mitochondrial complex III (ubiquinol cytochrome c
reductase) shows a two- to threefold increase on two in-
dependent spots, and mitochondrial complex V (ATP
synthase) has a twofold higher abundance in PD speci-
mens. Therefore, lower activity previously reported in the
literature should be related to the inhibition of mitochon-
drial enzymes in PD rather than a reduction in their
expression level; thus, the increased expression
observed here could be related to a compensatory
mechanism. In both approaches, however, it is not pos-
sible to distinguish the contribution of nigral neurons from
that of glial cells in SNpc homogenates.
Complexin I, profilin, and L-type calcium channel d sub-
unit all appear to be more expressed in PD patients.
Complexins are particularly abundant in presynaptic
terminals, where they play an important role in modulating
neurotransmitter release by exocytosis [41]. It has been
suggested that complexin overexpression could enhance
the probability of vesicle fusion upon influx of Ca21 ions
by increasing the number of vesicles close to full fusions.
It appears of peculiar interest the fact that L-type channels
are more expressed in PD, as it was reported for hippo-
campus specimens from AD patients [42]. Increased den-
sity of L-type Ca21 channels was actually associated to
selective neuronal death in hippocampus in AD. These
channels allow Ca21 influx after a change in membrane
potential due to glutamate binding to AMPA/kainate
receptors. Also in PD, the increase of calcium influx might
constitute an additional risk factor for involved neurons.
Actually, most of the results described here concern pre-
synaptic proteins; since our specimens are composed by
mesencephalic SN, the findings described are probably
related to modifications of afferent fibers to nigral dopa-
minergic neurons as a consequence of the extensive SN
cell death. In this view, two possible considerations could
be made: first, the increase of presynaptic proteins in
afferent terminals could be a mechanism to increase do-
pamine release by nigrostriatal neurons; second, this
possible afferent hyperactivity could also involve gluta-
matergic fibers from subthalamic nucleus, supporting, at
least partially, the excitotoxic hypothesis for SN degen-
eration [43]. Concerning profilin, it is a cytoskeleton-
interacting protein that binds to actin monomers resulting
in cytoskeletal changes. This finding could therefore be
suggestive of modifications of neurofilaments at the SNpc
level that takes place during the neurodegenerative pro-
cess of PD. Unlike a similar work on AD brain areas [44],
cytoplasmic Cu,Zn-SOD (spot 109) and a-crystallin B
chain (spots 102 and 103) do not appear here to be pres-
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ent in increased amount in PD SN tissue with respect to
the controls. Ubiquitin (spot 142) appears in all maps with
comparable intensities. This aspect has to be related to
the hypothesis that an impairment in UCH-L1 activity [45],
that would reduce the availability of ubiquitin monomers
for further ubiquitin tagging of proteins to be degraded, is
a minor factor in sporadic PD [46].
In conclusion, we have identified proteomic coordinates
of 44 proteins expressed in human SN and a comparison
between controls and PD patients have been made. Our
findings are consistent with the view of oxidative stress
involvement in PD pathogenesis, as suggested by over-
expression of mitochondrial and ROS-scavenging pro-
teins. Moreover, our work provides information about a
possible potentiation mechanism of afferent signals to SN
following degeneration of dopaminergic neurons. Finally,
this extensive application of the proteomic approach to
understand the molecular basis of PD demonstrates the
great potentiality of this methodology in the field of neu-
rodegenerative disorders.
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6 Addendum
Table 1. Statistical analysis and identification of proteins from human SN of control subjects and PD patients
Spot Controls (%) PD (%) Calcul-
ated pI
Calculated
MW (kDa)
p
Wilcoxon
Protein Theoreti-
cal pI
Theoreti-
cal MW
(kDa)
ID % Seq.
covered
1 6.632 6 5.188 1.629 6 1.410 4.462
119 637
64 446.37
0.002 Neurofilament M 4.90 102 316 P07197 28.6
2 1.365 6 1.974 0.525 6 0.483 4.245 83 313 0.331
3 1.060 6 0.856 0.775 6 0.552 4.746 83 313 0.574
4 6.867 6 3.386 3.075 6 1.741 4.462 69 118 0.001 Neurofilament L 4.66 61 646 P07196 43.6
5 0.285 6 0.129 0.258 6 0.158 5.050 63 521 0.689
6 0.380 6 0.215 0.420 6 0.387 5.150 63 249 0.456
7 0.378 6 0.126 0.317 6 0.126 5.222 62 979 0.438
8 0.263 6 0.109 0.195 6 0.074 5.291 62 844 0.252
9 0.186 6 0.103 0.251 6 0.121 6.186 64 623 0.867 Serum albumin 5.67 66 472 P02768 21.4
10 0.231 6 0.141 0.345 6 0.110 5.351 64 345 0.613
11 0.159 6 0.170 0.414 6 0.226 6.514 64 207 0.152
12 0.371 6 0.520 0.290 6 0.186 7.386 61 125 0.645
Pyruvate kinase,
M2 isozyme
7.95 57 783 P14786 33.4
13 0.495 6 0.329 0.547 6 0.282 7.534 61 125 0.721
14 0.328 6 0.264 0.407 6 0.206 7.780 61 386 0.235
15 0.250 6 0.149 0.184 6 0.058 5.310 59 088 0.388
16 0.279 6 0.201 0.398 6 0.172 5.406 58 840 0.541
17 0.211 6 0.084 0.382 6 0.151 5.499 58 716 0.167
18 0.371 6 0.486 0.465 6 0.185 6.924 55 956 1.427
Glu dehydrogenase 1,
mitochondrial
6.71 56 009 P00367 21
19 0.447 6 0.293 0.345 6 0.139 7.049 55 840 1.257
20 0.286 6 0.076 0.353 6 0.219 7.157 55 493 0.837
21 0.341 6 0.216 0.246 6 0.150 7.224 55 608 0.955
22 0.388 6 0.158 0.390 6 0.169 7.295 55 608 1.242
23 0.491 6 0.193 0.562 6 0.214 7.591 56 073 0.808
24 1.444 6 1.157 1.270 6 0.651 8.022 56 073 1.269 ATP synthase a-chain,
mitochondrial
8.28 55 209 P25705 32.9
25 0.121 6 0.091 0.172 6 0.107 5.027 51 747 0.643
Glial fibrillary acidic
protein, astrocyte
5.42 49 880 P14136 56.9
26 0.282 6 0.185 0.310 6 0.306 5.127 51 432 1.164
27 0.398 6 0.277 0.557 6 0.375 5.029 51 016 0.613
28 0.677 6 0.399 0.511 6 0.391 5.291 51 224 0.963
29 1.199 6 0.591 0.845 6 0.574 5.393 51 224 0.114
30 1.521 6 0.736 0.930 6 0.611 5.493 51 224 0.077
31 1.319 6 1.016 0.694 6 0.393 5.583 51 224 0.222
32 0.936 6 0.747 0.589 6 0.541 5.590 51 224 0.423
33 0.750 6 0.527 0.698 6 0.390 6.734 50 913 1.175
34 1.782 6 0.547 1.904 6 0.740 7.034 50 605 0.758
35 1.229 6 0.500 1.908 6 0.779 7.036 50 503 0.114
36 0.103 6 0.059 0.069 6 0.033 4.668 45 013 0.412
37 0.154 6 0.090 0.101 6 0.007 4.718 44 838 0.230
38 0.271 6 0.188 0.123 6 0.022 4.762 44 925 0.073
39 0.271 6 0.103 0.162 6 0.057 4.810 44 838 0.073
40 0.280 6 0.113 0.192 6 0.059 4.854 44 664 0.164
41 0.315 6 0.146 0.176 6 0.044 4.908 44 491 0.257
42 0.204 6 0.097 0.298 6 0.183 7.190 42 404 0.354 Fructose-bisphosphate
aldolase C
6.46 39 325 P09972 36.1
43 0.253 6 0.156 0.421 6 0.193 7.261 43 640 0.222 Aspartate aminotransferase,
cytoplasmic
6.57 46 116 P17174 38.1
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Table 1. Continued
Spot Controls (%) PD (%) Calcul-
ated pI
Calculated
MW (kDa)
p
Wilcoxon
Protein Theoreti-
cal pI
Theoreti-
cal MW
(kDa)
ID % Seq.
covered
44 0.495 6 0.288 0.605 6 0.247 8.033 46 081 0.435 Phosphoglycerate kinase 1 8.30 44 597 P00558 20.01
45 0.221 6 0.194 0.453 6 0.239 8.219 45 991 0.065
46 0.136 6 0.058 0.185 6 0.092 7.935 42 163 0.435
47 0.218 6 0.083 0.268 6 0.142 8.124 41 844 0.524
48 0.111 6 0.051 0.169 6 0.094 8.271 41 765 0.435
49 0.084 6 0.031 0.075 6 0.049 4.605 41 844 0.442
50 0.154 6 0.090 0.093 6 0.068 4.652 41 765 0.235
51 0.228 6 0.127 0.141 6 0.128 4.696 41 686 0.161
52 0.218 6 0.088 0.177 6 0.164 4.746 41 607 0.645
53 0.258 6 0.097 0.168 6 0.114 4.599 40 225 0.108
54 0.301 6 0.094 0.212 6 0.124 4.643 40 075 0.154
55 0.499 6 0.163 0.321 6 0.233 4.683 40 000 0.277
56 0.274 6 0.290 0.475 6 0.289 4.734 40 075 0.148
57 0.146 6 0.085 0.169 6 0.115 4.886 37 376 0.762
58 0.148 6 0.118 0.321 6 0.126 5.493 36 513 0.073 Guanine nucleotide-binding
protein b-subunit 1
5.60 37 377 P04901 27.6
59 0.255 6 0.165 0.509 6 0.258 5.731 36 513 0.053
60 0.343 6 0.297 0.268 6 0.095 7.450 36 775 0.860 Glyceraldehyde 3-phosphate
dehydrogenase
8.58 35 922 P04406 30.5
61 0.665 6 0.384 0.548 6 0.261 7.610 36 775 0.596
62 1.146 6 0.511 1.048 6 0.764 7.865 36 578 0.331
63 1.810 6 0.580 1.770 6 1.254 8.140 36 448 0.377
64 1.479 6 0.474 1.518 6 0.712 8.327 36 318 0.724
65 0.253 6 0.180 0.354 6 0.152 4.772 33 976 0.345
66 0.290 6 0.161 0.495 6 0.276 4.385 31 699 0.161 14-3-3 protein e 4.67 29 174 P42655 65.9
67 0.323 6 0.314 0.295 6 0.276 4.485 31 646 1.269
68 0.136 6 0.128 0.115 6 0.072 4.486 29 327 1.245 14-3-3 protein g 4.80 28 171 P35214 44.7
69 0.234 6 0.191 0.251 6 0.093 4.531 29 096 0.383
70 0.294 6 0.179 0.422 6 0.251 4.533 29 188 0.336
71 0.180 6 0.081 0.272 6 0.141 4.589 29 096 0.272
72 0.119 6 0.164 0.167 6 0.152 4.655 29 142 0.083
73 0.445 6 0.239 0.557 6 0.363 6.916 27 566 0.860 Phosphoglycerate mutase 1 6.75 28 672 P18669 38.3
74 2.247 6 0.841 1.755 6 0.581 7.183 27 525 0.190
75 0.648 6 0.116 0.461 6 0.176 7.378 27 650 0.024
76 0.378 6 0.561 0.399 6 0.307 5.144 26 057 1.530
77 1.346 6 0.810 1.763 6 0.663 5.291 25 869 0.222 Ubiquitin thiolesterase L1 5.33 24 824 P09936 43
78 0.604 6 0.702 0.663 6 0.462 5.373 25 795 0.222
79 0.274 6 0.431 0.191 6 0.082 6.140 26 019 0.366
80 1.187 6 0.739 1.436 6 0.674 6.665 25 944 0.480 Dihydropteridine reductase 6.90 25.803 P09417 55.3
81 0.371 6 0.240 0.318 6 0.112 6.810 25 982 0.798
82 0.219 6 0.126 0.181 6 0.060 6.920 25 982 0.681
83 0.354 6 0.287 0.552 6 0.293 7.079 25 869 0.162
84 0.358 6 0.214 0.258 6 0.114 7.187 25 869 0.673
85 0.641 6 0.334 0.562 6 0.219 7.269 25 944 0.724
86 0.132 6 0.085 0.184 6 0.078 5.144 21 759 1.242
87 0.132 6 0.100 0.232 6 0.116 5.160 20 391 0.050 ATP synthase D chain,
mitochondrial
5.22 18 360 O75947 63.7
88 0.426 6 0.766 0.284 6 0.112 5.439 21 685 1.059
89 0.800 6 0.330 1.596 6 0.496 5.573 21 661 0.004 Peroxiredoxin 2 5.66 21 891 P32119 42.9
90 0.205 6 0.223 0.271 6 0.148 5.830 22 419 0.299
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Table 1. Continued
Spot Controls (%) PD (%) Calcul-
ated pI
Calculated
MW (kDa)
p
Wilcoxon
Protein Theoreti-
cal pI
Theoreti-
cal MW
(kDa)
ID % Seq.
covered
91 0.073 6 0.094 0.118 6 0.029 6.277 23 210 0.043 Ubiquinol-cytochrome c
reductase iron-sulfur
subunit, mitochondrial
6.30 21 616 P47985 23.5
92 0.327 6 0.240 0.428 6 0.155 6.415 22 527 0.272
93 0.152 6 0.058 0.454 6 0.125 6.803 24 387 0.003 Ubiquinol-cytochrome c
reductase iron-sulfur
subunit, mitochondrial
6.30 21 616 P47985 25
94 0.120 6 0.141 0.153 6 0.168 6.924 22 084 0.731 Superoxide dismutase [Mn] 6.86 22 204 P04179 21.7
95 0.300 6 0.170 0.300 6 0.172 7.149 22 135 1.000
96 0.515 6 0.303 0.752 6 0.285 7.348 22 160 0.077
97 0.161 6 0.077 0.352 6 0.107 7.753 22 912 0.121
98 0.604 6 0.341 0.941 6 0.453 8.283 22 605 0.181 Peroxiredoxin 1 8.27 22 110 Q06830 37.2
99 1.120 6 0.576 1.075 6 0.566 7.299 21 303 0.596 a-crystallin B chain 6.76 20 159 O43416 35.6
100 3.777 6 0.971 3.535 6 0.691 7.675 21 140 0.930
101 0.306 6 0.166 0.292 6 0.262 8.025 21 256 1.530 Phosphatidylethanolamine-
binding protein
7.43 20 925 P30086 55.4
102 1.135 6 0.680 0.926 6 0.795 7.123 20 455 0.251 a-crystallin B chain 6.76 20 159 P02511 34.3
103 6.636 6 1.345 6.027 6 1.745 7.325 20 295 0.480
104 0.211 6 0.118 0.511 6 0.262 5.160 20 391 0.114 Ferritin heavy chain 5.30 21.907 P02794 36.9
105 0.313 6 0.294 0.771 6 0.729 5.410 19 513 1.464
106 0.336 6 0.213 0.372 6 0.247 4.181 19 498 0.943
107 0.046 6 0.031 0.111 6 0.081 4.422 18 465 0.147
108 0.146 6 0.086 0.068 6 0.054 4.437 17 951 0.111
109 0.477 6 0.341 0.585 6 0.208 5.596 18 210 0.289 Superoxide dismutase
[Cu-Zn]
5.70 15 804 P00441 49
110 1.032 6 0.659 1.369 6 0.682 5.752 18 241 0.480
111 0.418 6 0.197 0.409 6 0.149 5.508 18 034 0.959 Stathmin 5.77 17 171 P16949 37.8
112 0.107 6 0.087 0.340 6 0.107 6.633 18 272 0.200 Myelin basic protein 6.00 21 522 P02686-
2 (iso-
form)
24.4
113 0.037 6 0.025 0.227 6 0.169 6.693 18 324 0.095
114 0.088 6 0.090 0.271 6 0.139 6.799 18 376 0.143
115 0.084 6 0.098 0.209 6 0.092 6.946 18 359 0.381
116 0.055 6 0.057 0.157 6 0.092 7.068 18 341 0.229
117 0.335 6 0.363 0.185 6 0.030 7.172 18 324 1.600
118 0.042 6 0.010 0.191667 7.254 18 376 2.000
119 0.577 6 0.497 0.848 6 0.529 8.160 17 870 0.351 Cofilin, non-muscle isoform 8.22 18 502 P23528 47
120 0.512 6 0.287 0.815 6 0.422 7.469 17 024 0.162 Peptidyl-prolyl cis-trans
isomerase A
7.82 17 881 P05092 34.1
121 0.299 6 0.399 0.300 6 0.147 7.749 17 066 0.606
122 0.304 6 0.261 0.557 6 0.389 7.943 16 996 0.077
123 0.141 6 0.081 0.377 6 0.214 4.202 16 591 0.008 Chain 2: L-type calcium
channel d-subunit
4.47 16 466 P54289 36.7
124 0.060 6 0.038 0.148 6 0.091 4.431 16 850 0.065 Chain 1: factor X light chain 4.59 15 725 P00742 53.2
125 0.591 6 0.398 0.807 6 0.384 4.527 16 838 0.232
126 0.132 6 0.219 0.066 6 0.054 4.462 15 654 0.876 Cytochrome c oxidase poly-
peptide Va, mitochondrial
4.88 12 513 P20674 36.7
127 0.093 6 0.024 0.277 6 0.152 4.540 15 835 0.008 Complexin 1 4.93 15 030 O14810 36.6
128 0.239 6 0.140 0.431 6 0.111 4.769 15 442 0.189 Galectin-1 5.34 14 584 P09382 60.4
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Table 1. Continued
Spot Controls (%) PD (%) Calcul-
ated pI
Calculated
MW (kDa)
p
Wilcoxon
Protein Theoreti-
cal pI
Theoreti-
cal MW
(kDa)
ID % Seq.
covered
129 0.059 6 0.024 0.149 6 0.068 5.926 15 541 0.010 Splice isoform IIB
of Profilin II
5.81 14 957 P35080-
2 (iso-
form)
33.1
130 0.044 6 0.025 0.103 6 0.037 6.287 15 422 0.008 Fatty acid-binding protein 6.34 14 727 P05413 40.2
131 0.265 6 0.246 0.359 6 0.197 6.858 15 402 0.114 Hemoglobin b-chain 6.81 15 867 P02023 87.7
132 0.373 6 0.183 0.568 6 0.066 7.138 15 481 0.006
133 3.263 6 0.663 3.633 6 1.587 7.276 15 139 1.000
134 10.5426 2.087 10.369 6 4.734 7.446 15 130 0.190
135 1.448 6 0.564 1.811 6 1.374 7.637 15 222 0.791
136 4.941 6 2.140 2.857 6 0.796 8.022 14 886 1.829 Hemoglobin a-chain 8.73 15 126 P01922 83.7
137 4.816 6 2.614 3.471 6 2.445 8.496 14 861 1.655
138 0.156 6 0.128 0.271 6 0.156 4.103 14 041 0.284 Thioredoxin 4.82 11 606 P10599 46.2
139 0.104 6 0.079 0.272 6 0.252 4.232 14 041 0.214
140 1.580 6 0.935 1.234 6 0.431 5.782 14 240 0.743 Cytocrome c oxidase
polypeptide VIb
6.79 10 061 P14854 89.4
141 0.143 6 0.034 0.308 6 0.145 6.376 7000 0.111 Chain 2: neuregulin-4 5.46 6663 Q8WWG1 50.8
142 3.762 6 1.089 3.630 6 1.055 7.175 13 699 1.057 Ubiquitin 7.99 9071 Q15843 65.8
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